Skip to main content
Clinical Trials/CTRI/2018/07/014823
CTRI/2018/07/014823Not yet recruiting未知

An exploratory pilot clinical validation study to correlate clinical outcome between physician decided therapy and its CANscriptTM response prediction in metastatic Castration Resistant Prostate Cancer (mCRPC) patients.

Dr SK Raghunath0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
未知
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Inclusion Criteria

  • 1. Patient diagnosed as mCRPC with rising PSA
  • levels and for whom physician has already
  • decided to initiate abiraterone alone or in
  • combination with other drug
  • 2. Men >= 18 years of age
  • 3. ECOG performance status ï?£ 2
  • 4. Patientâ??s tumour (primary or metastatic
  • sites) must be amenable to a fresh tumour
  • biopsy sampling using surgical/excision
  • biopsy or core biopsy, so that CANscript can
  • be performed. Decision to perform biopsy
  • will be outside the study protocol and as
  • per routine clinical decision by treating
  • 5. Patient willing to provide written informed
  • consent for study participation

Exclusion Criteria

  • 1. Patient has any medical condition, which in the
  • opinion of the investigator places the patient
  • at an unacceptably high risk for study related

Investigators

Sponsor
Dr SK Raghunath

Similar Trials